- 专利标题： TG2 inhibitor piperazine compounds and uses thereof
-
申请号： US16093751申请日： 2017-04-13
-
公开(公告)号： US10894777B2公开(公告)日： 2021-01-19
- 发明人: Jeffrey W. Keillor , Abdullah Akbar , Richard L. Eckert , Matthew Fisher , Gail V. W. Johnson
- 申请人： UNIVERSITY OF OTTAWA , UNIVERSITY OF MARYLAND, BALTIMORE , UNIVERSITY OF ROCHESTER
- 申请人地址： CA Ottawa; US MD Baltimore; US NY Rochester
- 专利权人： UNIVERSITY OF OTTAWA,UNIVERSITY OF MARYLAND, BALTIMORE,UNIVERSITY OF ROCHESTER
- 当前专利权人： UNIVERSITY OF OTTAWA,UNIVERSITY OF MARYLAND, BALTIMORE,UNIVERSITY OF ROCHESTER
- 当前专利权人地址： CA Ottawa; US MD Baltimore; US NY Rochester
- 代理机构： BCF LLP
- 国际申请： PCT/IB2017/052162 WO 20170413
- 国际公布： WO2017/179018 WO 20171019
- 主分类号： A61K31/4965
- IPC分类号： A61K31/4965 ; C07D295/10 ; C07D241/04 ; C07C317/36 ; C07D405/06
摘要：
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer. Compounds of Formula I, and pharmaceutically acceptable salts thereof, are provided:
公开/授权文献
- US20190389814A1 TG2 INHIBITOR COMPOUNDS AND USES THEREOF 公开/授权日：2019-12-26
信息查询
